IN2014DN00277A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN00277A IN2014DN00277A IN277DEN2014A IN2014DN00277A IN 2014DN00277 A IN2014DN00277 A IN 2014DN00277A IN 277DEN2014 A IN277DEN2014 A IN 277DEN2014A IN 2014DN00277 A IN2014DN00277 A IN 2014DN00277A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutical composition
- present
- derivative
- peg
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555084P | 2011-11-03 | 2011-11-03 | |
| PCT/US2012/063447 WO2013067449A1 (en) | 2011-11-03 | 2012-11-02 | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN00277A true IN2014DN00277A (pt) | 2015-06-05 |
Family
ID=48192863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN277DEN2014 IN2014DN00277A (pt) | 2011-11-03 | 2012-11-02 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10391056B2 (pt) |
| EP (1) | EP2773346B1 (pt) |
| JP (1) | JP6205095B2 (pt) |
| KR (1) | KR101688898B1 (pt) |
| CN (1) | CN103957912B (pt) |
| AU (1) | AU2012332176B2 (pt) |
| CA (1) | CA2850955C (pt) |
| IN (1) | IN2014DN00277A (pt) |
| SG (1) | SG10201609199YA (pt) |
| TW (3) | TWI549679B (pt) |
| WO (1) | WO2013067449A1 (pt) |
| ZA (1) | ZA201403195B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
| TWI526446B (zh) * | 2013-09-27 | 2016-03-21 | 中國醫藥大學附設醫院 | 喜樹鹼的新穎２０（ｓ）－磺基脒衍生物及其抗腫瘤劑的用途 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| JP6426194B2 (ja) | 2013-11-01 | 2018-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物の結晶形態及びその使用 |
| US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| BR112019004463A2 (pt) | 2016-09-08 | 2019-05-28 | Kala Pharmaceuticals Inc | formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso |
| KR102664243B1 (ko) * | 2018-01-19 | 2024-05-08 | 데루타-후라이 화마 가부시키가이샤 | 암 환자의 치료에 유용한 오줌의 알칼리제 |
| CN111632144B (zh) * | 2020-07-06 | 2022-07-29 | 聊城大学 | 一种高载药量的光-化疗双功能纳米粒及其制备方法 |
| UY39743A (es) | 2021-04-29 | 2022-11-30 | Abbvie Inc | Conjugados de anticuerpo anti-c-met y fármaco |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5731316A (en) | 1996-01-30 | 1998-03-24 | The Stehlin Foundation For Cancer Research | Derivatives of camptothecin and methods of treating cancer using these derivatives |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| WO2001085131A2 (en) | 2000-05-11 | 2001-11-15 | Celator Technologies Inc. | Lipid carrier compositions for improved drug retention |
| US7485320B2 (en) * | 2000-09-25 | 2009-02-03 | Industrial Technology Research Institute | Liposome for incorporating large amounts of hydrophobic substances |
| US6350756B1 (en) | 2001-01-18 | 2002-02-26 | California Pacific Medical Center | Camptothecin derivatives |
| US6403604B1 (en) | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| AP2255A (en) | 2004-06-01 | 2011-07-21 | Yakult Honsha Kk | Irinotecan preparation. |
| ES2562052T3 (es) | 2004-06-18 | 2016-03-02 | Kabushiki Kaisha Yakult Honsha | Preparación liposómica que contiene camptotecina ligeramente soluble en agua |
| CA2584279C (en) * | 2004-11-05 | 2015-01-27 | Index Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal drug formulations |
| CA2617873A1 (en) | 2005-08-10 | 2007-02-15 | Novartis Ag | Formulations for 7-(t-butoxy)iminomethyl camptothecin |
| US7875602B2 (en) * | 2005-10-21 | 2011-01-25 | Sutter West Bay Hospitals | Camptothecin derivatives as chemoradiosensitizing agents |
| CN101652125A (zh) * | 2007-02-01 | 2010-02-17 | 希格马托制药工业公司 | 包含喜树碱衍生物的药物组合物 |
| CN101283983A (zh) * | 2007-10-26 | 2008-10-15 | 南京长澳医药科技有限公司 | 一种稳定的喜树碱类药物脂质体组合物 |
| CN101485629B (zh) | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
| US8168648B2 (en) | 2009-03-06 | 2012-05-01 | Taiwan Liposome Co., Ltd. | Camptothecin derivatives and uses thereof |
| CN101869712B (zh) | 2009-04-21 | 2016-01-20 | 财团法人工业技术研究院 | 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物 |
| CN102018670B (zh) | 2010-11-15 | 2015-08-12 | 宜昌人福药业有限责任公司 | 一种抗癌制剂 |
| US20140135357A1 (en) | 2012-11-12 | 2014-05-15 | Taiwan Liposome Company, Ltd. | Dose regime for camptothecin derivatives |
-
2012
- 2012-11-02 CA CA2850955A patent/CA2850955C/en active Active
- 2012-11-02 IN IN277DEN2014 patent/IN2014DN00277A/en unknown
- 2012-11-02 EP EP12844678.8A patent/EP2773346B1/en active Active
- 2012-11-02 WO PCT/US2012/063447 patent/WO2013067449A1/en active Application Filing
- 2012-11-02 US US14/353,120 patent/US10391056B2/en active Active
- 2012-11-02 AU AU2012332176A patent/AU2012332176B2/en not_active Ceased
- 2012-11-02 TW TW104101201A patent/TWI549679B/zh active
- 2012-11-02 TW TW101140626A patent/TWI480042B/zh active
- 2012-11-02 CN CN201280052300.3A patent/CN103957912B/zh active Active
- 2012-11-02 SG SG10201609199YA patent/SG10201609199YA/en unknown
- 2012-11-02 JP JP2014540166A patent/JP6205095B2/ja active Active
- 2012-11-02 TW TW105123079A patent/TWI619496B/zh active
- 2012-11-02 KR KR1020147008940A patent/KR101688898B1/ko active IP Right Grant
-
2014
- 2014-05-02 ZA ZA2014/03195A patent/ZA201403195B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101688898B1 (ko) | 2016-12-22 |
| TW201513865A (zh) | 2015-04-16 |
| ZA201403195B (en) | 2020-05-27 |
| EP2773346A4 (en) | 2015-08-19 |
| JP2014532727A (ja) | 2014-12-08 |
| CA2850955A1 (en) | 2013-05-10 |
| JP6205095B2 (ja) | 2017-09-27 |
| AU2012332176B2 (en) | 2016-03-10 |
| AU2012332176A1 (en) | 2014-01-16 |
| WO2013067449A1 (en) | 2013-05-10 |
| TWI480042B (zh) | 2015-04-11 |
| TWI549679B (zh) | 2016-09-21 |
| US10391056B2 (en) | 2019-08-27 |
| EP2773346A1 (en) | 2014-09-10 |
| SG10201609199YA (en) | 2016-12-29 |
| EP2773346B1 (en) | 2021-10-27 |
| TW201325591A (zh) | 2013-07-01 |
| TW201637654A (zh) | 2016-11-01 |
| TWI619496B (zh) | 2018-04-01 |
| CN103957912B (zh) | 2019-04-05 |
| NZ620933A (en) | 2016-05-27 |
| KR20140057384A (ko) | 2014-05-12 |
| CN103957912A (zh) | 2014-07-30 |
| CA2850955C (en) | 2019-11-19 |
| US20140294973A1 (en) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN00277A (pt) | ||
| CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| WO2013052699A3 (en) | Novel quinoxaline inhibitors of pi3k | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| MX2013010340A (es) | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| PH12015500686A1 (en) | Nicotine composition | |
| MX2019003693A (es) | Formulaciones de insulina de accion prolongada. | |
| IN2014MN02214A (pt) | ||
| MX2015000813A (es) | Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona. | |
| GB2507884A (en) | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current | |
| MX369121B (es) | Formulacion farmaceutica acuosa de tapentadol para administracion oral. | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| IN2015DN01119A (pt) | ||
| WO2014165607A3 (en) | Aromatic-cationic peptide formulations, compositions and methods of use | |
| EP4360621A3 (en) | Formulations of bendamustine | |
| MY173890A (en) | Crystalline naloxol-peg conjugate | |
| IN2014DN08598A (pt) | ||
| IN2015DN04151A (pt) | ||
| NZ711500A (en) | Engineering a control drug release profile via liposome compositions in both aqueous and non-aqueous compartments | |
| IN2014CN03214A (pt) | ||
| TN2014000060A1 (en) | Benzothiazolone compound | |
| WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same | |
| WO2014015137A3 (en) | Compositions and methods for treating dysproliferative diseases |